Clinical Trial Update: Autologous Tumor Tissue Antigen-sensitized DC-CIK Cells Combined With Chemotherapy for Esophageal Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating autologous tumor tissue antigen-sensitized dendritic cell-cytokine-induced killer (DC-CIK) cells in combination with chemother…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Digestive System Neoplasms
• Esophageal Cancer

Drugs mentioned

• Autologous tumor tissue antigen-sensitized dendritic cell-cytokine-induced killer (DC-CIK) cells
• Chemotherapy (unspecified regimen)

Snippet

Sponsor: Shenzhen Hornetcorn Bio-technology Company, LTD | Conditions: Esophageal Neoplasms, Neoplasms | Phase 2 | Status: UNKNOWN